Bill number does not exist. Enter a vaild keyword.
Facebook Twitter Youtube Channels MY MGA
Original
Chamber
1st
Reading
Referral
to Cmte
2nd
Reading
3rd
Reading
Opposite
Chamber
1st
Reading
Referral
to Cmte
2nd
Reading
3rd
Reading
Review in
Original Chamber
Passed Both
Chambers
Conf. Cmte
(if necessary)
To Governor
Title
Pharmacists - Required Notification and Authorized Substitution - Lower-Cost Drug or Device Product
Sponsored by
Senator Hershey
Status
In the Senate - Hearing 2/16 at 1:00 p.m.
Analysis
Fiscal and Policy Note
Synopsis
Requiring a pharmacist, or the pharmacist's designee who is under certain supervision, to inform a certain consumer of the availability of a therapeutically equivalent brand name drug that is the lowest cost alternative to the originally prescribed drug or device and the cost difference between the therapeutically equivalent drug or device and the prescribed drug; altering the cost difference of which a pharmacist is required to inform a retail consumer; requiring a certain determination to be made based on a certain drug benefit; etc.
Details
Cross-filed with: HB0429
Bill File Type: Regular
Effective Date(s): October 1, 2021
Legislation History
Chamber
Senate
Calendar Date
1/26/2021
Legislative Date
1/26/2021
Action
First Reading Education, Health, and Environmental Affairs
Proceedings
Chamber
Senate
Calendar Date
2/02/2021
Legislative Date
2/02/2021
Action
Hearing 2/16 at 1:00 p.m.
Proceedings
Chamber Calendar Date Legislative Date Action Proceedings
Senate 1/26/2021 1/26/2021 First Reading Education, Health, and Environmental Affairs
Text - First - Pharmacists - Required Notification and Authorized Substitution - Lower-Cost Drug or Device Product
Senate 2/02/2021 2/02/2021 Hearing 2/16 at 1:00 p.m.
Last Updated: 2/18/2021 12:48 PM
Click to return on the top page